ERBB2 and breast cancer: Notably, the Basal subtype displayed distinctly elevated OncoRibo-68 scores relative to Luminal A, Luminal B, and HER2+ subtypes (Figure 4I), reinforcing the notion that enhanced RiBi is a hallmark of particularly aggressive breast cancers.